Walvax Biotechnology

Walvax Biotechnology

China - Kunming
Biotechnology

Focus: Development, manufacturing, and distribution of vaccines and blood products

Walvax Biotechnology is a life sciences company focused on Development, manufacturing, and distribution of vaccines and blood products.

Infectious DiseasesVaccines
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

RQ3013
COVID-19
Phase 1
Clinical Trials (1)
NCT05396573A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
Phase 1
202-CoV low adjuvant dose
COVID-19
Phase 1
Clinical Trials (1)
NCT04982068Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
Phase 1
RQ3013
COVID-19
Phase 1
Clinical Trials (1)
NCT05394012A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
Phase 1
Meningococcal Group ACYW135 Conjugate Vaccine
Meningococcal Infections
Phase 1
Clinical Trials (1)
NCT04236960Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.
Phase 1
ZR-202-CoV
COVID-19
Phase 1/2
Clinical Trials (1)
NCT05313022Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
Phase 1/2
202-CoV low adjuvant dose
COVID-19
Phase 2
Clinical Trials (1)
NCT04990544Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
Phase 2
Phase 3
Clinical Trials (1)
NCT05934890A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
Phase 3
Zerun HPV-9
Cervical Cancer
Phase 3
Clinical Trials (1)
NCT05580341Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
Phase 3
7-valent pneumococcal conjugate vaccine
Diseases Caused by Streptococcus Pneumoniae Serotypes
Phase 3
Clinical Trials (1)
NCT02736240Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)
Phase 3
SARS-CoV-2 mRNA Vaccine
COVID-19
Phase 3
Clinical Trials (1)
NCT04847102A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
Phase 3
Phase 3
Clinical Trials (1)
NCT02285036Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children
Phase 3
Yuxi Walvax MPV ACYW® vaccine
Neisseria Meningitides Meningitis
Phase 4
Clinical Trials (1)
NCT04450498A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2001
Portfolio: 12 clinical trials